KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
 - EconoTimes)
NEW ORLEANS, Jan. 06, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until January 17, 2017 to file lead plaintiff applications in a securities class action lawsuit against Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), if they purchased the Company’s securities between the expanded period of February 10, 2014 and December 9, 2016, inclusive (the “Class Period”). The action is pending in United States District Court, District of Connecticut.
What You May Do
If you purchased securities of Alexion and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 17, 2017.
About the Lawsuit
Alexion and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) Alexion employed improper sales practices with respect to its product Soliris; (ii) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and (iii) as a result of the foregoing, Alexion’s public statements were materially false and misleading at all relevant times.
Additionally, on December 12, 2016, Alexion announced the unscheduled departure of CEO David Hallal and CFO Vikas Sinha, who both resigned effective immediately.
On this news, the price of Alexion’s shares again plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
